• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.45% Nasdaq Up0.40%

    More On UGNEQ

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    Financials


    Unigene Laboratories Inc. (UGNEQ)

    -Other OTC
    0.00 0.00(0.00%) Apr 27
    ProfileGet Profile for:
    Unigene Laboratories Inc.
    81 Fulton Street
    Boonton, NJ 07005
    United States - Map
    Phone: 973-265-1100
    Fax: 973-335-0972
    Website: http://www.unigene.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:53

    Business Summary 

    Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and drug delivery of peptides for therapeutic use in the United States. Its patented oral and nasal drug delivery technologies deliver therapeutically useful amounts of various peptides into the bloodstream. The company offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. It is also developing oral calcitonin that has completed a Phase III testing for the treatment of osteoporosis. In addition, the company is also developing a pre-clinical anorexigenic peptide, UGP281 for obesity. It has license agreements with Tarsa Therapeutics, Inc. and Novartis Pharma AG for the development of oral calcitonin program. Unigene Laboratories, Inc. was founded in 1980 and is headquartered in Boonton, New Jersey. On July 2, 2013, Unigene Laboratories Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Unigene Laboratories Inc.

    Key Executives 
     PayExercised
    Mr. Ashleigh W. Palmer , 53
    Chief Exec. Officer, Pres and Director
    427.00K0.00
    Mr. Brian Zietsman CPA, 52
    Chief Financial Officer and Principal Accounting Officer
    169.00K0.00
    Dr. Nozer M. Mehta Ph.D., 68
    Chief Scientific Officer
    267.00K0.00
    Dr. Jane Pepper M.B.A, Ph.D.,
    Sr. Director of Bus. Devel.
    N/AN/A
    Dr. Allen Bloom Ph.D., Esq., 72
    Sec.
    N/AN/A
    Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders